Video explainer Early results from a multicenter trial on SGLT2 inhibitors in heart failure with preserved ejection fraction The trial reports a reduction in the composite primary outcome. Here's what was measured, who was included, and the limits to keep in mind before changing practice.
[Demo] SGLT2 inhibition in heart failure with preserved ejection fraction: a multicenter trial Demo Journal of Cardiology · 2026 doi:10.5555/demo.hfpef.2026
Human expert review completed 2 reviews
Rigor Qualified reviewers assessed the methods and statistics. This does not mean the result is settled. Reach (likes, shares) never changes this label.
Qualified reviewers assessed the methods and statistics. This does not mean the result is settled.
Statistical review · Sound with caveats
Analysis follows the registered plan. The subgroup by ejection fraction should be read as exploratory; no multiplicity correction was applied.
Analysis matches the prespecified plan Effect sizes come with confidence intervals Signed review · Conflicts: None declared · Reviewed version 1 · 5h ago
Methodological assessment · Sound
Randomized, double-blind design appropriate for the question. Primary outcome prespecified. Attrition balanced between arms.
Outcomes were prespecified Design is appropriate for the question Signed review · Conflicts: None declared · Reviewed version 1 · 5h ago
Discussion (2) These findings are consistent with previous studies, but heterogeneity across patient populations matters here.
Is there any data on patients over 75?